TFAP2A antibodies are laboratory-generated proteins that bind specifically to the TFAP2A transcription factor, which regulates genes involved in cell differentiation, craniofacial development, and cancer progression . These antibodies are used to visualize TFAP2A in experimental techniques such as:
Western blotting (WB)
Immunohistochemistry (IHC)
Immunofluorescence (IF/ICC)
Chromatin immunoprecipitation (ChIP)
Enzyme-linked immunosorbent assay (ELISA)
Their utility extends to both basic research (e.g., studying developmental biology) and clinical investigations (e.g., cancer biomarker analysis) .
Cervical Cancer: TFAP2A is overexpressed in cervical squamous carcinoma, where its knockdown suppresses tumor cell proliferation and invasion . Antibodies like ab108311 were instrumental in validating these findings via WB and IHC .
Lung Adenocarcinoma (LUAD): High TFAP2A levels correlate with poor prognosis and metastasis. Studies using TFAP2A antibodies demonstrated its role in promoting epithelial–mesenchymal transition (EMT) via PSG9/TGF-β signaling .
Gallbladder Cancer: TFAP2A inhibition reduces tumor aggressiveness, as shown through antibody-based assays .
TFAP2A knockout mice exhibit severe craniofacial defects and neural tube abnormalities. Antibodies such as 3B5 have been used to map TFAP2A expression in embryonic tissues, confirming its role in neural crest cell migration .
Knockout Validation: Abcam’s ab108311 was validated using TFAP2A-knockout HeLa cells, showing no cross-reactivity with other proteins .
Multi-Species Reactivity: Proteintech’s 67076-1-Ig detects TFAP2A in human, mouse, and rat samples, making it suitable for cross-species studies .
Epitope Mapping: The 3B5 antibody targets the DNA-binding domain (a.a. 166–197), critical for studying TFAP2A’s transcriptional activity .
Diagnostic Potential: TFAP2A expression in LUAD and cervical cancer tissues, detected via IHC, serves as a prognostic marker for metastasis and survival .
Therapeutic Targets: Antibody-based studies identified TFAP2A-regulated pathways (e.g., PSG9/TGF-β) as potential targets for anti-metastatic therapies .
Dual Role in Cancer: TFAP2A acts as an oncogene in some cancers (e.g., LUAD) but as a tumor suppressor in others (e.g., hepatocellular carcinoma), complicating therapeutic strategies .
Antibody Variability: Differences in epitope recognition between clones (e.g., 3B5 vs. 13019-3-AP) may affect experimental reproducibility .
Mechanistic Studies: Advanced techniques like single-cell sequencing combined with TFAP2A antibodies could unravel cell-type-specific regulatory networks.
Clinical Trials: Antibodies may facilitate TFAP2A-targeted drug delivery or biomarker panels for precision oncology.